pISSN 1226-6051
eISSN 2508-786X

Fig. 1.

Download original image
Fig. 1. The percentage of people who did agree (blue) or did not agree (navy) the mandatory submission of DSUR for all drugs when introduced in South Korea. The figure shows how respondents who did not agree (in percentages) prioritize what should be introduced first. A: New Drugs (including Biomedicine), B: Incrementally Modified Drugs (including Bio-better), C: New Combination Drugs (all ingredients licensed), D: Generic Drugs (including Bio-similar), E: Drugs designated for Risk Management Plan or Re-examination
Korean J Clin Pharm 2021;31:53-60 https://doi.org/10.24304/kjcp.2021.31.1.53
© 2021 Korean J Clin Pharm